mRNA-based vaccine efficacious in preventing symptomatic RSV infection

1. In this randomized-controlled trial, an mRNA-based vaccine was efficacious at preventing symptomatic infection with respiratory syncytial virus (RSV) involving one respiratory sign or symptom in 68.4% of participants. 2. The mRNA-based vaccine was associated with a higher rate of mild to moderate adverse events than placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: RSV

Related Keywords

, Minute Medicine Inc , Rating Level , Infectious Disease , Mrna 1345 Vaccine , Mrna Based Vaccine , Public Health , Pulmonology , Respiratory Syncytial Virus Rsv , Respirology , Rsv ,